首页 | 本学科首页   官方微博 | 高级检索  
     

灯盏生脉胶囊用于缺血性脑卒中二级预防的成本效用分析
引用本文:李薇,朱晓晨,朱贺,韩晟. 灯盏生脉胶囊用于缺血性脑卒中二级预防的成本效用分析[J]. 中国新药杂志, 2021, 0(5): 474-480
作者姓名:李薇  朱晓晨  朱贺  韩晟
作者单位:北京大学医药管理国际研究中心
摘    要:
目的:对于中国缺血性脑卒中患者,分析使用灯盏生脉胶囊联合标准二级预防方案或单用标准预防方案进行二级预防的成本效用.方法:基于全社会视角,构建Markov模型,模拟患者5年的成本和质量调整生命年.模型包括4个健康状态,分别是未复发卒中、复发卒中不依赖他人照料(mRSO-2)、复发卒中依赖他人照料(mRS3-5)和死亡.临...

关 键 词:缺血性脑卒中二级预防  灯盏生脉胶囊  马尔可夫模型  成本效用分析

Cost-utility analysis of Dengzhan Shengmai capsule for secondary stroke prevention
LI Wei,ZHU Xiao-chen,ZHU He,HAN Sheng. Cost-utility analysis of Dengzhan Shengmai capsule for secondary stroke prevention[J]. Chinese Journal of New Drugs, 2021, 0(5): 474-480
Authors:LI Wei  ZHU Xiao-chen  ZHU He  HAN Sheng
Affiliation:(International Research Center for Medicinal Administration,Peking University,Beijing 100191,China)
Abstract:
Objective: This study aims to analyze the cost-utility of the add-on of Dengzhan Shengmai( DZSM) capsule with standard medical therapy and standard medical therapy alone in secondary stroke prevention.Methods: A Markov model was constructed based on the societal perspective and the costs and health unities were simulated for a time horizon of 5 years. The model included 4 health states,included healthy,recurrent strokeindependent( mRS0-2),recurrent stroke-dependent( mRS3-5) and death. Clinical data and utilities for the modelling analysis were obtained from published literatures. Direct costs included medication costs obtained from public database,and costs for hospitalization,post-discharge rehabilitation service,and secondary prevention were sourced from published literatures. 2019 inflation-adjusted costs were calculated using Consumer Price Index( CPI) for medical care. Indirect costs included loss of salary for patients and their families caused by the disease which were derived from China statistical yearbook. Results: Base-case analysis results showed that the incremental costs of DZSM group( 29 284 RMB) over 5 years were higher than the control group( 21 551 RMB). The incremental health utilities of DZSM group( 3. 91 QALYs) over 5 years were also greater than the control group( 3. 81 QALYs).The incremental costs of the two group were 7 734 RMB,while the incremental utilities were 0. 1 QALYs. The incremental cost-utility ratio was 74 479 RMB/QALY,which equals to approximately 1. 05 times of GDP per capita and less than 3 times of GDP per capita,indicating that the add-on of DZSM capsule with standard medical therapy were more cost-effective. Sensitivity analyses revealed robust results. Conclusion: Compared to standard medical therapy alone,the add-on of DZSM capsule has economic advantages in secondary stroke prevention.
Keywords:secondary stroke prevention  Dengzhan Shengmai capsule  Markov model  cost-utility analysis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号